Mizuho reiterates Corvus Pharmaceuticals stock rating on pipeline
Covered in this story
Tracked from this story
Mizuho’s $27 target on $CRVS is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Mizuho’s track record →Call it yourself
No member calls on $CRVS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Corvus Pharmaceuticals Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.